---
title: "Old Targets Are Crowded, but They Can Still Make Money"
url: https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html
date: 2026-06-06
lang: en
category: "商業分析系列"
tags: ["BD and Licensing","Business development","Biotech business analysis","Drug development"]
summary: "Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy."
json: https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.json
publisher: Drugnews｜藥時事 (https://drugnews.com.tw/)
---
This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers.

## Core Thesis

An old target is not automatically a bad target. It becomes unattractive only when the new product cannot explain why it deserves a place against existing therapies. Differentiation may come from convenience, safety, combination logic, biomarker segmentation, or market access.

## Why It Matters

The business lesson is that novelty and value are not the same thing. Investors should ask whether a company has a clear wedge into an existing market, not whether the mechanism sounds brand new.

## Reading Framework

Drugnews reads this topic through five practical questions:

- What new evidence or business signal has actually changed?
- Which risks remain unresolved in clinical development, CMC, regulation, or commercialization?
- Does the event improve strategic optionality for partnership, licensing, financing, or M&A?
- Can the company convert scientific progress into durable market position?
- Does the information change valuation, or only create short-term attention?

## What To Watch Next

Readers should watch for follow-up data, trial design changes, safety signals, regulatory feedback, manufacturing readiness, payer response, competitive readouts, partnership activity, and whether management can turn the story into measurable execution.

## Original Chinese Edition

This English page is designed to make Drugnews analysis searchable and readable for English-language audiences while preserving the Chinese original as the primary source edition.

Read the original Chinese article: [老靶點都很捲，但不是不能賺錢](https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html)

This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.